Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial — known as the NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol — enrolled 1,377 children and young people with advanced solid tumours, non-Hodgkin lymphomas, or histiocytic disorders (a group of rare diseases involving certain immune cells). The trial was a screening study, meaning its main purpose was to test participants' tumours for specific genetic changes that might match them to one of several targeted treatment sub-studies, rather than to directly test a single drug. The reported data shows that the primary thing being measured was the proportion of eligible participants whose tumours contained a genetic change that could potentially be targeted by one of the drugs being studied in the linked sub-studies. According to the results reported on ClinicalTrials.gov, that figure was 28% — meaning that out of the eligible participants screened, 28 in every 100 were found to have a genetic change that matched them to at least one of those sub-studies. It is worth noting that participants enrolled after a certain protocol update (Amendment 4) were not included in this calculation, as the screening approach changed at that point. The reported data shows that the secondary outcome — looking at how tumours without these targetable genetic changes responded to targeted treatment — had no numbers submitted to ClinicalTrials.gov. Similarly, several additional planned analyses, such as mapping the broader genetic landscape of these childhood cancers and examining inherited genetic mutations, were listed but had no numerical results reported in the submitted data. These results as reported represent only what was measured during screening and cannot be used to draw conclusions about individual cases. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 41166674) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Interstitial Lung Disease Trial, Active, Not Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Children and young people who are at least 12 months old and no older than 21 years of age at the time of joining the study.
- Patients who have a solid tumor, non-Hodgkin lymphoma, a histiocytic disease (such as Langerhans cell histiocytosis or histiocytic sarcoma), or a brain/central nervous system tumor that has come back or has stopped responding to treatment.
- Patients whose cancer was confirmed by a tissue sample (biopsy) at the time of their original diagnosis or when the cancer returned — with some exceptions for certain brain tumors where this may not be required (confirm with trial site).
- Patients who have a stored tumor tissue sample available from after the cancer returned or progressed, OR who are planning to have a procedure to obtain one that their doctor believes may be beneficial (for patients enrolled up to end of 2021).
- Patients enrolled from 2022 onward who have a tumor genetic/molecular testing report from an approved laboratory, performed on a sample taken after the cancer returned or progressed.
- Patients who are well enough to carry out at least some daily activities, as measured by standard medical scoring tools (confirm with trial site for specific scores required).
- Patients whose cancer can be measured on a scan, based on imaging taken within the last 56 days before joining.
- Patients whose kidney function is at an acceptable level, based on age-appropriate blood test results (confirm with trial site for specific values).
- Patients whose liver function blood test results are within acceptable limits.
- Patients who are able to swallow tablets or capsules whole (unless the specific treatment they are assigned to states otherwise).
- Patients who have recovered sufficiently from side effects of any previous cancer treatments, and who have waited the required amount of time since their last treatment before starting a new treatment sub-study (confirm with trial site for specific waiting periods).
- Patients with cancer that has spread to the bone marrow may still be eligible, provided their blood counts meet the required levels.
Who may not be able to join:
- People who are pregnant or breastfeeding, as the treatments may be harmful to an unborn baby or infant.
- People of childbearing or fathering potential who are not willing to use effective contraception during the study.
- Patients with Hodgkin lymphoma or a condition called plexiform neurofibroma.
- Patients currently taking steroid medications (such as prednisone) whose dose has not been stable or reducing for at least 7 days before joining a treatment sub-study.
- Patients currently taking other experimental/investigational drugs or other cancer treatments at the same time as the study treatment.
- Patients taking medications to prevent graft-versus-host disease after a bone marrow transplant (such as cyclosporine or tacrolimus).
- Patients who have an infection that is not under control.
- Patients who have previously received a solid organ transplant (such as a kidney, heart, or liver transplant).
- Patients whose tumor tissue sample was processed using a standard acid-based method to remove calcium (decalcification), as this may make the sample unsuitable for testing (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Donald W Parsons, Children's Oncology Group
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Proportion of Pediatric Patients Whose Advanced Tumors Have Pathway Alterations That Can be Targeted by Select Anti-cancer Drugs
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.